Great Lakes Advisors LLC Reduces Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Great Lakes Advisors LLC cut its holdings in Gilead Sciences, Inc. (NASDAQ:GILDFree Report) by 20.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,389 shares of the biopharmaceutical company’s stock after selling 1,351 shares during the period. Great Lakes Advisors LLC’s holdings in Gilead Sciences were worth $404,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in GILD. Cetera Investment Advisers grew its holdings in Gilead Sciences by 9.2% during the 1st quarter. Cetera Investment Advisers now owns 57,967 shares of the biopharmaceutical company’s stock valued at $3,446,000 after purchasing an additional 4,877 shares during the last quarter. Baird Financial Group Inc. grew its holdings in Gilead Sciences by 3.9% during the 1st quarter. Baird Financial Group Inc. now owns 448,409 shares of the biopharmaceutical company’s stock valued at $26,660,000 after purchasing an additional 16,643 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its holdings in Gilead Sciences by 44.3% during the 1st quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 8,642 shares of the biopharmaceutical company’s stock valued at $514,000 after purchasing an additional 2,654 shares during the last quarter. Donaldson Capital Management LLC grew its holdings in Gilead Sciences by 12.5% during the 1st quarter. Donaldson Capital Management LLC now owns 5,763 shares of the biopharmaceutical company’s stock valued at $343,000 after purchasing an additional 641 shares during the last quarter. Finally, Ergoteles LLC bought a new position in Gilead Sciences during the 1st quarter valued at about $2,304,000. 82.33% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

GILD has been the topic of a number of research analyst reports. Royal Bank of Canada dropped their target price on shares of Gilead Sciences from $78.00 to $77.00 and set a “sector perform” rating on the stock in a research note on Tuesday, November 14th. Deutsche Bank Aktiengesellschaft started coverage on Gilead Sciences in a report on Thursday, November 9th. They issued a “hold” rating and a $75.00 target price for the company. Barclays raised their price target on Gilead Sciences from $82.00 to $85.00 and gave the company an “equal weight” rating in a research note on Tuesday, January 23rd. Leerink Partnrs reaffirmed a “market perform” rating on shares of Gilead Sciences in a research note on Wednesday, October 11th. Finally, UBS Group lowered their price objective on shares of Gilead Sciences from $85.00 to $84.00 and set a “neutral” rating for the company in a research note on Wednesday, November 8th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $87.46.

Read Our Latest Stock Analysis on GILD

Insider Buying and Selling

In related news, insider Johanna Mercier sold 8,242 shares of the stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $85.23, for a total value of $702,465.66. Following the transaction, the insider now owns 82,729 shares in the company, valued at approximately $7,050,992.67. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, insider Johanna Mercier sold 8,242 shares of the firm’s stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $85.23, for a total transaction of $702,465.66. Following the sale, the insider now owns 82,729 shares of the company’s stock, valued at approximately $7,050,992.67. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $85.78, for a total transaction of $428,900.00. Following the sale, the chief financial officer now directly owns 101,534 shares in the company, valued at approximately $8,709,586.52. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.

Gilead Sciences Stock Performance

GILD stock opened at $77.72 on Wednesday. The firm has a market cap of $96.84 billion, a price-to-earnings ratio of 16.68, a PEG ratio of 0.91 and a beta of 0.20. The firm has a 50-day simple moving average of $80.90 and a two-hundred day simple moving average of $78.28. Gilead Sciences, Inc. has a one year low of $72.87 and a one year high of $87.86. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.20 and a current ratio of 1.34.

Gilead Sciences (NASDAQ:GILDGet Free Report) last announced its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing the consensus estimate of $1.76 by ($0.04). The company had revenue of $7.12 billion during the quarter, compared to analysts’ expectations of $7.10 billion. Gilead Sciences had a net margin of 21.45% and a return on equity of 39.30%. The business’s revenue for the quarter was down 3.7% compared to the same quarter last year. During the same period in the previous year, the business earned $1.67 earnings per share. On average, equities analysts forecast that Gilead Sciences, Inc. will post 6.76 EPS for the current fiscal year.

About Gilead Sciences

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.

Read More

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.